Antigens and immunoevasins: Opponents in cytomegalovirus immune surveillance

Nature Reviews Immunology

Volumn 2, Issue 11, 2002, Pages 831-844

  Reddehase, Matthias J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; IMMUNOEVASIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; HLA ANTIGEN CLASS 1; IE1 PROTEIN, CYTOMEGALOVIRUS; IMMEDIATE EARLY PROTEIN; VIRUS ANTIGEN;

ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGENICITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EFFECTOR CELL; HUMAN; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; T LYMPHOCYTE; TARGET CELL; VACCINATION; VIRUS INFECTION; VIRUS LATENCY; VIRUS TRANSMISSION; ANIMAL; ARTICLE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; IMMUNOSURVEILLANCE; PHYSIOLOGY; RECURRENT DISEASE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOLOGIC SURVEILLANCE; MICE; RECURRENCE; VIRAL PROTEINS; VIRUS LATENCY;

EID: 0036831249     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri932     Document Type: Review

References (148)

1. van Regenmortel, M. H. V. et al. (eds) in Virus Taxonomy. Seventh Report of the International Committee on Taxonomy of Viruses 203-225 (Academic Press, San Diego, 2000).
2. Reddehase, M. J. The immunogenicity of human and murine cytomegaloviruses. Curr. Opin. Immunol. 12, 390-396 (2000).
3. Ploegh, H. Viral strategies of immune evasion. Science 280, 248-253 (1998).
4. Alcami, A. & Koszinowski, U. H. Viral mechanisms of immune evasion. Immunol. Today 9, 447-455 (2000).
5. Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J. & Ploegh, H. L. Viral subversion of the immune system. Annu. Rev. Immunol. 18. 861-926 (2000).
6. Andrews, D. M., Andoniou, C. D., Granucci, F., Ricciardi-Castagnoli, P. & Degli-Esposti, M. A. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nature Immunol. 2, 1077-1084 (2001).
7. Raftery, M. J. et al. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15, 997-1009 (2001).
8. Moutaftsi, M., Mehl, A. M., Borysiewicz, L. K. & Tabi, Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99, 2913-2921 (2002).
9. Wiertz, E., Hill, A., Tortorella, D. & Ploegh, H. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol. Lett. 57, 213-216 (1997).
10. Hengel, H., Brune, W. & Koszinowski, U. H. Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol. 6, 190-197 (1998).
11. Hengel, H. & Koszinowski, U. H. in Herpesviruses and Immunity (eds Bendinelli, M., Friedman, H. & Medveczky, P.) 247-264 (Plenum, New York, 1998).
12. Hengel, H. et al. Cytomegaloviral control of MHC class I function in the mouse. Immunol. Rev. 168, 167-176 (1999).
13. Johnson, D. C. & Hegde, N. R. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus. Curr. Top. Microbiol. Immunol. 269, 101-115 (2002).
14. Farrell, H. E., Davis-Poynter, N. J., Andrews, D. M. & Degli-Esposti, M. A. Function of CMV-encoded MHC class I homologues. Curr. Top. Microbiol. Immunol. 269, 131-151 (2002).
15. Braud, V. M., Tomasec, P. & Wilkinson, G. W. G. Viral evasion of natural killer cells during human cytomegalovirus infection. Curr Top. Microbiol. Immunol. 269, 117-130 (2002).
16. Mocarski, E. S. Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion Trends Microbiol. 10, 332-339 (2002).
17. Pass, R. F. in Fields Virology 4th edn (eds Knipe, D. M. & Howley, P. M.) 2675-2705 (Lippincott Williams & Wilkins. Philadelphia, 2001).
18. + T lymphocytes. J. Exp. Med. 169, 1199-1212 (1989).
19. + T-cell-based immunotherapy of CMV disease in the mouse model.
20. Podlech, J., Holtappels, R., Wirtz, N., Steffens, H.-P. & Reddehase, M. J. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone-marrow transplantation. J. Gen. Virol. 79, 2099-2104 (1998).
21. + T cells are not anergic in situ and resolve productive infection of the lungs.
22. Barry, S. M., Johnson, M. A. & Janossy, G. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant. 26, 591-597 (2000).
23. Bukowski, J. F. Woda, B. A. & Welsh, R. M. Pathogenesis of murine cytomegalovirus infection in natural-killer-cell-depleted mice. J. Virol. 52, 119-128 (1984).
24. Scalco, A. A. et al. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J. Immunol. 149, 581-589 (1992).
25. Salazar-Mather, T. P., Orange, J. S. & Biron, C. A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med. 187, 1-14 (1998).
26. Daniels, K. A. et al. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J. Exp. Med. 194, 29-44 (2001).
27. Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B. & Lanier, L. L. Direct recognition of cytomegalovirus by activating and inhibitory NK-cell receptors. Science 296, 1323-1326 (2002).
28. Welsh, R. M., Brubaker, J. O., Vargas-Cortes, M. & O'Donnell, C. L. Natural killer (NK)-cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK-cell-dependent control of virus infections occur independently of T- and B-cell function. J. Exp. Med. 173, 1053-1063 (1991).
29. Lathbury, L. J., Allan, J. E., Shellam, G. R. & Scalzo, A. A. Effect of host genotype in determining the relative roles of natural killer cells and T cells in mediating protection against murine cytomegalovirus infection. J. Gen. Virol. 77, 2605-2613 (1996).
30. Reddehase, M. J., Jonjic, S., Weiland, F., Mutter, W. & Koszinowski, U. H. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J. Virol. 62, 1061-1065 (1988).
31. Jonjic, S. et al. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179, 1713-1717 (1994).
32. + T lymphocytes. J. Virol. 64, 5457-5464 (1990).
33. Polic, B. et al. Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo J. Gen. Virol. 77, 217-225 (1996).
34. + T cells present in pulmonary infiltrates during interstitial pneumonia are cytolytic effector cells that lyse mCMV-infected target cells in the early (E) phase.
35. Alterio de Goss, M. et al. Control of cytomegalovirus in bone-marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells. J. Virol. 72, 7733-7744 (1998).
36. Reusser, P., Riddell, S. R., Meyers, J. D. & Greenberg, P. D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone-marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 18, 1373-1380 (1991).
37. + T-cell-based immunotherapy of CMV disease in humans.
38. Chee, M. S. et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol. 154, 125-169 (1990).
39. Rawlinson, W. D., Farrell, H. E. & Barrell, B. G. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70, 8833-8849 (1996).
40. Mocarski, E. S. & Courcelle, C. T. in Fields Virology 4th edn (eds Knipe, D. M. & Howley, P. M.) 2629-2673 (Lippincott Williams & Wilkins, Philadelphia, 2001).
41. Honess, R. W. & Rolzman, B. Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides. Proc. Natl Acad. Sci. USA 72, 1276-1280 (1975).
42. Reddehase, M. J., Keil, G. M. & Koszinowski, U. H. The cytolytic T-lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T-lymphocyte precursors. Eur. J. Immunol. 14, 56-61 (1984).
43. Reddehase, M. J. & Koszinowski, U. H. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312, 369-371 (1984). The first report of the immunogenicity of CMV immediate-early (IE) antigens.
44. Del Val, M. et al. Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J. Virol. 62, 3965-3972 (1988).
45. Reddehase, M. J., Rothbard, J. B. & Koszinowski, U. H. A pentapeptide as minimal antigenic determinant for MHC class-1-restricted T lymphocytes. Nature 337, 651-653 (1989). References 44 and 45 describe the molecular identification of the mCMV IE1 peptide, the first antigenic peptide to be defined for CMVs.
46. + T-cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T-cell recognition. J. Gen. Virol. 77, 2615-2623 (1996).
47. Jonjic, S., del Val, M., Keil, G. M., Reddehase, M. J. & Koszinowski, U. H. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J. Virol. 62, 1653-1658 (1988).
48. Del Val, M. et al. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol. 65, 3641-3646 (1991).
49. Scalzo, A. A. et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 69, 1306-1309 (1995).
50. Gonzales-Armas, J. C., Morello, C. S., Cranmer, L. D. & Spector, D. H. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. 70, 7921-7928 (1996).
51. Holtappels, R. et al. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J. Virol. 74, 1871-1884 (2000).
52. dhaplotype. J. Virol. 76, 151-164 (2002).
53. Wills, M. R. et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity and T-cell-receptor usage of pp65-specific CTL. J. Virol. 70, 7569-7579 (1996).
54. + T lymphocytes in healthy seropositive donors. J. Virol. 74, 8140-8150 (2000).
55. Gilbert, M. J., Riddell, S. R., Plachter, B. & Greenberg, R. D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383, 720-722 (1996).
56. Borysiewicz, L. K. et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate-early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 168, 919-931 (1988). The first report of the immunogenicity of the IE1 protein of hCMV.
57. + T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73, 8179-8184 (1999).
58. Gyulai, Z. et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-exon 4, 9B, pp150 and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J. Infect. Dis. 181, 1537-1546 (2000).
59. + T-cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality and phenotype. J. Infect. Dis. 165, 1025-1034 (2002).
60. Wagner, M., Gutermann, A., Podlech, J., Reddehase, M. J. & Koszinowski, U. H. MHC class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J. Exp. Med. 196, 805-816 (2002). This study used a complete set of immunoevasin gene-deletion mutants of mCMV to show the effects of the three known MHC-class-1-targeting immunoevasins in all seven possible combinations.
61. Del Val, M. et al. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J. Exp. Med. 176, 729-738 (1992).
62. Thäle, R. et al. Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. J. Virol. 69, 6098-6105 (1995).
63. Ziegler, H. et al. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 6, 57-66 (1997).
64. Ziegler H., Muranyi, W., Burgert, H.-G., Kremmer, E. & Koszinowski, U. H. The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J. 19, 870-881 (2000). References 61-64 describe the discovery and the molecular mode of action of the first immunoevesin of CMVs.
65. Barnes, P. D. & Grundy, J. E. Down-regulation of the class I HLA heterodimer and β-microglobulin on the surface of cells infected with cytomegalovirus. J. Gen. Virol. 73, 2395-2403 (1992). Early evidence for the intracellular retention of MHC class I complexes in fibroblasts infected with hCMV.
66. Jones, T. R. et al. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl Acad. Sci. USA 93, 11327-11333 (1996).
67. Ahn, K. et al. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl Acad. Sci. USA 93, 10990-10995 (1996).
68. Warren, A. P., Ducroq, D. H., Lehner, P. J. & Borysiewicz, L. K. Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J. Virol. 68, 2822-2829 (1994).
69. Wiertz, E. J. H. J. et al. SEC61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384, 432-438 (1996). This study unravels the molecular details of the retrograde translocation of MHC class I molecules for proteasomal degradation, mediated by the hCMV immunoevasin gpUS2.
70. Wiertz, E. J. E. J. et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769-779 (1996).
71. van der Wal, F. J., Kikkert, M. & Wiertz, E. The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. Curr. Top. Microbiol. Immunol. 269, 37-56 (2002).
72. Del Val, M., Münch, K., Reddehase, M. J. & Koszinowski, U. H. Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell 58, 305-315 (1989).
73. Gold, M. et al. The murine cytomegalovirus Immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL, but does not alter the immunodominance of the M45-specific CD8 T-cell response in vivo. J. Immunol. 169, 359-365 (2002).
74. Krmpotic, A. et al. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T-cell control in vivo. J. Exp. Med. 190, 1285-1295 (1999). The first evidence for in vivo attenuation of CMV pathogenicity by deletion of an MHC-class-I-targeting immunoevasin.
75. + T lymphocytes and NK cells in vivo. Nature Immunol. 3, 529-535 (2002). The first example of an immunoevasin that inhibits adaptive and innate immune functions simultaneously. See also reference 109.
76. Jones, T. R. et al. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 69, 4830-4841 (1995). Pioneering work mapping immunoevasin genes to the unique short region of the hCMV genome.
77. Kleijnen, M. F. et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 16, 685-694 (1997).
78. Kavanagh, D. G., Koszinowski, U. H. & Hill, A. B. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J. Immunol. 167, 3894-3902 (2001).
79. Gewurz, B. E., Wang, E. W., Tortorella, D. Schust, D. J. & Ploegh, H. L. Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. J. Virol. 75, 5197-5204 (2001).
80. Rehm, A. et al. Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J. Virol. 76, 5043-5050 (2002). A demonstration of cell-type-specific differences in the hierarchy of immunoevasin functions.
81. Kavanagh, D. G., Gold, M. C., Wagner, M., Koszinowski, U. H. & Hill, A. B. The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J. Exp. Med. 194, 967-977 (2001). The first report of functional cooperation between immunoevasins.
82. Longmate, J. et al. Population coverage by HLA class-I-restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 52, 165-173 (2001).
83. Morello, C. S., Cranmer, L. D. & Spector, D. H. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J. Virol. 74, 3696-3708 (2000).
84. Holtappels, R. et al. Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65) J. Virol. 75, 6584-6600 (2001). Using different approaches, references 83 and 84 document the protective antiviral potential of subdominant viral peptides.
85. Riddell, S. R., Rabin, M., Geballe, A. P., Britt, W. J. & Greenberg, P. D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146, 2795-2804 (1991).
86. Pepperl, S., Münster, J., Mach, M., Harris, J. R. & Plachter, B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. 74, 6132-6146 (2000).
87. Jahn, G. et al. Map position and nucleotide sequence of the gene for the large structural phosphoprotein of human cytomegalovirus. J. Virol. 61, 1358-1367 (1987).
88. Sigal, L. J., Crotty, S., Andino, R. & Rock, K. L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398, 77-80 (1999).
89. Heath, W. R. & Carbone, F. R. Cross-presentation in viral immunity and self-tolerance. Nature Rev. Immunol. 1, 126-134 (2001).
90. Fonteneau, J.-F., Larsson, M. & Bhardwaj, N. Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr. Opin. Immunol. 14, 471-477 (2002).
91. + T cells by dendritic cells. J. Virol. 74, 10018-10024 (2000).
92. Tabi, Z., Moutaftsi, M. & Borysiewicz, L. K. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class-I-restricted cytotoxic T-cell responses induced by cross-presentation of viral antigens. J. Immunol. 166, 5695-5703 (2001).
93. Plachter, B., Sinzger, C. & Jahn, G. Cell types involved in replication and distribution of human cytomegalovirus. Adv. Virus Res. 46, 195-261 (1996).
94. Fisher, S., Genbacev, O., Maidjl, E. & Pereira, L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis J. Virol. 74, 6806-6820 (2000).
95. Reddehase, M. J., Mutter, W. & Koszinowski, U. H. In vivo application of recombinant interleukin-2 in the immunotherapy of established cytomegalovirus infection. J. Exp. Med. 165, 650-656 (1987).
96. Benz, C. et al. Efficient downregulation of major histocompatibility complex class I molecules in human epithelial cells infected with cytomegalovirus. J. Gen. Virol. 82, 2061-2070 (2001).
97. Hengel, H. et al. Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J. Virol 74, 7861-7868 (2000).
98. Stoddard, C. A. et al. Peripheral-blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J. Virol. 68, 6243-6253 (1994).
99. Hanson, L. K. et al. Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis. J. Virol. 73, 5970-5980 (1999).
100. Hengel, H., Lucin, P., Jonjic, S., Ruppert, T. & Koszinowski, U. H. Restoration of cytomegalovirus antigen presentation by γ-interferon combats viral escape. J. Virol. 68, 280-297 (1994).
101. Geginat, G., Ruppert, T., Hengel, H., Holtappels, R. & Koszinowski, U. H. IFN-γ is a prerequisite for optimal antigen processing of viral peptides in vivo. J. Immunol. 158, 3303-3310 (1997). References 100 and 101 provide evidence in vitro and in vivo of a role for IFN-γ in the restoration of antigen presentation in the presence of immunoevasins.
102. Benz, C. & Hengel, H. MHC class-I-subversive gene functions of cytomegalovirus and their regulation by interferons - an intricate balance. Virus Genes 21, 39-47 (2000).
103. Holtappels, R. et al. Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J. Virol. 76, 6044-6053 (2002). Identification of an E-phase peptide of mCMV that constitutively escapes all immunoevasin functions.
104. Polic, B. et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188, 1047-1054 (1998).
105. Holtappels, R., Pahl-Seibert, M.-F., Thomas, D. & Reddehase, M. J. Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L-lo memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J. Virol. 74, 11495-11503 (2000).
106. Kurz, S. K. & Reddehase, M. J. Patchwork pattern of transcriptional reactivation in the lungs indicates sequential checkpoints in the transition from murine cytomegalovirus latency to recurrence. J. Virol. 73, 8612-8622 (1999).
107. Reddehase, M. J. et al. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J. Exp. Med. 179, 185-193 (1994).
108. Steffens, H.-P., Kurz, S., Holtappels, R. & Reddehase, M. J. Preemptive CD8-T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genome and reduces the risk of virus recurrence. J. Virol. 72, 1797-1804 (1998).
109. Kärre, K. Clever, cleverer, cleverest. Nature Immunol. 3, 505-506 (2002).
110. Jahn, G., Pohl, W., Plachter, B. & von Hintzenstern, J. Congenital cytomegalovirus infection with fatal outcome. Dtsch. Med. Wochenschr. 113, 424-427 (1988).
111. Boppana, S. B., Rivera, L. B., Fowler, K. B., Mach, M. & Britt, W. J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med. 344, 1366-1371 (2001).
112. Ho, M. Cytomegalovirus. Biology and Infection (Plenum Medical Book Company, New York and London, 1982).
113. Britt, W. J. Vaccines against human cytomegalovirus: time to test. Trends Microbiol. 4, 34-38 (1996).
114. Gonczol, E. & Plotkin, S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Exp. Opin. Biol. Ther. 1, 401-412 (2001).
115. Stratton, K. R., Durch, J. S. & Lawrence, R. S. (eds) Vaccines for the 21st Century. A Tool for Decisionmaking. Committee to Study Priorities for Vaccine Development (Division of Health Promotion and Disease Prevention, Institute of Medicine, The National Academies, Washington, 2001). Arguments in favour of a vaccine against hCMV (see Further Information).
116. Dorsch-Häsler, K. et al. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate-early mRNA in murine cytomegalovirus. Proc. Natl Acad. Sci. USA 82, 8325-8329 (1985).
117. Keil, G. M., Ebeling-Keil, A. & Koszinowski, U. H. Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J. Virol. 61, 1901-1908 (1987).
118. Messerle, M., Keil, G. M. & Koszinowski, U. H. Structure and expression of murine cytomegalovirus immediate-early gene 2. J. Virol. 65, 1638-1643 (1991).
119. Messerle, M., Bühler, B., Keil, G. M. & Koszinowski, U. H. Structural organization, expression and functional characterization of the murine cytomegalovirus immediate-early gene 3. J. Virol. 66, 27-36 (1992).
120. Gribaudo, G. et al. Murine cytomegalovirus stimulates cellular thymidylate synthese gene expression in quiescent cells and requires the enzyme for replication. J. Virol. 74, 4979-4987 (2000).
121. Cardin, R. D., Abenes, G. B., Stoddart, A. & Mocarski, E. S. Murine cytomegalovirus IE2, an activator of gene expression, is dispensable for growth and latency in mice. Virology 209, 236-241 (1995).
122. Angulo, A., Ghazal, P. & Messerle, M. The major immediate-early gene ie3 of mouse cytomegalovirus is essential for viral growth. J. Virol. 74, 11129-11136 (2000).
123. depitope is generated and translocated into the endoplasmic reticulum as an 11-mer precursor peptide. J. Immunol. 167, 1515-1521 (2001). This paper describes the molecular details of mCMV IE1 processing and peptide translocation into the endoplasmic reticulum.
124. Serwold, T., Gonzales, F., Kim, J., Jacob, R. & Shastri, N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419, 480-483 (2002).
125. Shastri, N., Schwab, S. & Serwold, T. Producing nature's gene-chips. The generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20, 463-493 (2002).
126. Rammensee, H.-G., Bachmann, J. & Stevanovic, S. MHC Ligands and peptide Motifs (Molecular Biology Intelligence Unit, Landes Bioscience, Austin, Texas, 1997).
127. Reddehase, M. J. & Koszinowski, U. H. Redistribution of critical major histocompatibility complex and T-cell receptor-binding functions of residues in an antigenic sequence after biterminal substitution. Eur. J. Immunol. 21, 1687-1701 (1991).
128. Reusch, U. et al. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 18, 1081-1091 (1999).
129. Ahn, K. et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6, 613-621 (1997).
130. Hengel, H. et al. Viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 6, 623-632 (1997).
131. Lehner, P. J., Karttunen, J. T., Wilkinson, G. W. G. & Cresswell, P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc. Natl Acad. Sci. USA 94, 6904-6909 (1997). References 129-131 describe the discovery and mode of action of hCMV immunoevasin gpUS6, the first immunoevasin to be discovered that targets TAP-dependent peptide translocation into the endoplasmic reticulum.
132. Gewurz, B. E. et al. Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc. Natl Acad. Sci. USA 98, 6794-6799 (2001). The crystal structure of hCMV immunoevasin gpUS2 bound to HLA-A2.
133. Holtappels, R., Grzimek, N. K. A., Thomas, D & Reddehase, M. J. Early gene m18, a novel player in the immune response to murine cytomegalovirus. J. Gen. Virol. 83, 311-316 (2002).
134. d-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84. J. Gen. Virol. 81, 3037-3042 (2000).
135. Utz, U., Koenig, S., Coligan, J. E. & Biddison, W. E. Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J. Immunol. 149, 214-221 (1992).
136. Parker K. C. et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J. Immunol. 149, 3580-3587 (1992).
137. Hebart, H. et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ -enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem-cell transplantation. Blood 99, 3830-3837 (2002).
138. Solache, A. et al. Identification of three HLA-A*0201-restricted cytotoxic T-cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J. Immunol. 163, 5512-5518 (1999).
139. Diamond, D. J., York, J., Sun, J. Y., Wright, C. L. & Forman, S. J. Development of a candidate HLA A*0201-restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90, 1751-1767 (1997).
140. Masuoka, M. et al. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Viral Immunol. 14, 369-377 (2001).
141. + T-Cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98, 1872-1881 (2001).
142. Weekes, M. P., Wills, M. R., Mynard, K., Carmichael, A. J. & Sissons, J. G. P. The memory cytotoxic T-lymphocyte response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J. Virol. 73, 2099-2108 (1999).
143. Kern, F. et al. T-cell epitope mapping by flow cytometry. Nature Med. 4, 975-978 (1998).
144. Gavin, M. A., Gilbert, M. J., Riddell, S. R., Greenberg, P. D. & Bevan, M. J. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol. 151, 3971-3980 (1993).
145. + T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8 T-cell response. J. Immunol. 168, 5455-5464 (2002).
146. Retiere, C. et al. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J. Virol. 74, 3948-3952 (2000).
147. Frankenberg, N., Pepped-Klindworth, S., Meyer, R. G. & Plachter, B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295, 208-216 (2002).
148. Grzimek, N. K. A. et al. In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early enhancer of human cytomegalovirus. J. Virol. 73, 5043-5055 (1999).